Related Experiment Video
Updated: Apr 16, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
Published on: November 1, 2015
Morbidity and Mortality in Iranian Children with Juvenile Systemic Lupus erythematosus
Fariba Tavangar-Rad1, Vahid Ziaee2, Mohammad-Hassan Moradinejad3
1Growth and Development Research Center.
Insights
Juvenile systemic lupus erythematosus (JSLE) impacts multiple organs, with poorer prognosis in children. This study found a 10% mortality rate, with liver, cardiac, and pulmonary involvement significantly increasing mortality risk in pediatric SLE patients.
Area of Science:
- Pediatric Rheumatology
- Systemic Autoimmune Diseases
Background:
- Juvenile systemic lupus erythematosus (JSLE) is a significant rheumatologic condition affecting children, often with a poorer prognosis compared to adult-onset lupus.
- Understanding mortality and morbidity patterns in pediatric SLE is crucial for improving patient outcomes.
Purpose of the Study:
- To determine the mortality and morbidity rates in children diagnosed with systemic lupus erythematosus (SLE) in Iran.
- To identify factors associated with increased mortality in pediatric SLE.
Main Methods:
- A cross-sectional study evaluated 120 children with SLE from a pediatric rheumatology database (2004-2010).
- Data collected included demographics, age at diagnosis and study, organ involvement, remission status, and mortality.
- Statistical analysis identified significant differences in organ involvement across age groups and sexes, and associations with remission and mortality.
Main Results:
- The study included 120 pediatric SLE patients (77% female), with a mean follow-up of 56 months.
- The overall mortality rate was 10%.
- Musculoskeletal, oral ulcer, ophthalmic, cardiovascular, and renal involvement showed significant associations with age, sex, or remission status. Cardiac, pulmonary, and liver involvement were significantly associated with increased mortality.
Conclusions:
- The 1-year and 5-year survival rates were 97% and 89%, respectively.
- Liver, cardiac, and pulmonary involvement are critical factors associated with higher mortality in juvenile systemic lupus erythematosus.
- These findings highlight the importance of monitoring and managing these specific organ involvements in pediatric SLE for better survival rates.
Objective:
Juvenile systemic lupus erythematosus (JSLE) is a common rheumatologic disorder that involves multi organ systems. Prognosis of lupus in children may be poorer than in adults. In this study, we determined mortality and morbidity rates in the pediatric SLE in Iran.
Methods:
In a cross sectional study, we evaluated 120 children with SLE who had registered in our pediatric rheumatology database within 2004-2010. Data including sex, age, remission, age at the time of diagnosis, age at the time of study, various types of organ involvement, mortality and remission were extracted from this database. Findings : From 120 cases, 77% (92 cases) were females and 23% (28 cases) males (F:M=3.3). Mean follow up period was 56±32 months and mean age at the time of manifesting disease 10.34±2.9 years. Mortality rate was 10% (12 cases) in our investigation. Musculoskeletal involvement showed significant difference between various age groups (P<0.01), that was more frequent in group of 7 years and older. Frequency of oral ulcer and ophthalmic involvement in boys was significantly higher than in girls (P<0.05). Frequency of cardiovascular involvement (P<0.01) and renal involvement (P<0.01) was significantly higher in the patients who had no remission. There was a significant association between mortality rate and cardiac (P<0.02, OR=4.9), pulmonary (P<0.01, OR=10.167) and liver (P<0.05, OR=1.19) involvement.
Conclusion:
In our investigation 1-year survival rate was 97% and 5-year survival rate 89%. Liver, cardiac and pulmonary involvements have an association with higher mortality in JSLE patients.
Related Concept Videos
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Nephrotic Syndrome II : Assessment and Medical Management
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Nephrotic Syndrome I : Introduction

